glp-1 anti-obesity Agonists In Obesity MCT2D | 2023 Updates to
Description
Biological basis of cravings The hormone that these drugs mimic, GLP-1, is not only produced in the gut
Most patients tolerate the medication well, with the most common side effects being mild to moderate gastrointestinal symptoms
Results may vary based on diet, lifestyle, and individual physiology
Patients treated with Opdivo plus the two chemo agents and followed for approximately 33 months saw a 22% reduction in risk of death compared with chemotherapy alone
My colleagues, Tim Richards and Glynn Tonsor, and I will further explore these questions in future work
